Gesellschaft Fur Biotechnologische Forschung Mbh

Ciba-Geigy Corporation

Helmholtz-Zentrum Fur Infektionsforschung Gmbh

Helmholtz-Zentrum Fuer Infektionsforschung Gmbh

Gesellschaft Fur Biotechnologische Forschung Gmbh

Ganomycin

Hemholtz-Zentrum Fur Infektionsforschung Gmbh

Rolf Jansen

Herbert Irschik

Brigitte Kunze

Heinrich Steinmetz

Klaus Gerth

Hans Reichenbach

Norbert Bedorf

Wolfram Trowitzsch-Kienast

Gerhard Hofle

Florenz Sasse

Johannes P Pachlatko

Hermann Augustiniak

Edgar Forche

Dietmar Schomburg

Victor Wray

Gerhard H Ofle

Rolf Müller

Jennifer Herrmann

Kathrin Mohr

Stephan Hüttel

Ulrike Lindequist

Kenneth N Timmis

Anastasia Andreas

Gabriella Molinari

Antione Abou Fayad

Magally Romero-Tabarez

Dwi Andreas Santosa

Steffen Bernecker

Wolf J&uuml;lich

Ramzi Mothana

Katrin Jungmann-Sahner

Emilia Oueis

Nestor Zaburannyi

Antoine Abou Fayad

Sabrina Karwehl

The present invention relates to novel chlorotonil derivatives of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections and malaria. 

Chlorotonil derivatives

The invention provides novel Thuggacin-Type macrolide compounds which form rearrangement products forming a lacton bond to different carbon atoms. The novel compounds can be produced by fermentation ofandand can be isolated by adsorption and chromoatograhic processing steps. The compounds are found to have antibiotic activity. The invention also relates to Thuggacin A, Thuggacin B, Thuggacin C, 13-Methyl-Thuggacin A, Thuggacin CMC-A, Thuggacin CMC-B and Thuggacin CMC-C AS Antimycobacterial Agents.

Macrolide antibiotics and their use for medical purposes

The invention relates to a novel antibiotic from the macrolactin group and a microbial method for production of macrolactins and a novel isolated, of application as the producing strain for the known Macrolactin A and the novel derivative.

Antibiotic and method of production thereof

The present invention relates to a novel group of compounds having antibiotic, antifungal and/or cytostatic properties, which are obtainable from myxobacteria, especially of the genus, preferably. One representative of this group of compounds is currently named Disorazole Z and Disorazole Z-epoxide, respectively, with specific substituents and specific unsaturated bonds to its cyclic core structure: 

[object Object]

The present invention relates to novel biologically active compounds from fungi of the species DSM 13239, processes for their preparation, and their use. From the fruit body and mycelium of the species DSM 13239, extracts can be obtained which have antimicrobial activity and are suitable as preserving agents, for pharmaceutical and cosmetic preparations, for controlling infections, and for use in fish breeding. Antimicrobially active substances called ganomycins having activity against multiresistant germs are isolated from the extracts. The total synthesis of the ganomycins and their derivatization enables their use an antibiotics.

Biologically active compounds of Ganoderma pfeifferi DSM 13239

The invention relates to compounds of the following general formula I ##STR1## especially the compound of formula Ia referred to as thiangazole ##STR2## their pharmaceutically acceptable acid addition salts, processes for their preparation and therapeutic compositions and compositions that can be used in crop-protection.

Thiangazole, its preparation, compositions and use thereof

The invention relates to cyclic antibiotics of formula ##STR1## wherein the prefix R represents that the substituents on the adjacent carbon atom are in the R configuration; the prefix S represents that the substituents on the adjacent carbon atom are in the S configuration;

Macrocyclic antibodies

The invention relates to novel polycyclic alkaloids of formula ##STR1## in which R.sup.1 represents hydrogen or hydroxy, R.sup.2 represents hydrogen or acyl and A and B, independently of one another, each represents C.dbd.O or C--OH, and wherein the dashed line represents a C.dbd.C double bond at the position of the middle bond when A or B represents C.dbd.O, or at the position of the two outer bonds when A or B represents C--OH, a process for the manufacture of these compounds by fermentation of a novel microorganism of the species Myxococcus xanthus, the novel microorganism itself, pharmacetical preparations that contain the novel compounds, and the use of the novel compounds as antibiotics and as tumour-inhibiting agents and for the manufacture of pharmaceutical preparations.

Antibiotics from myxococcus

The invention relates to cyclic antibiotics of formula ##STR1## wherein the prefix R represents that the substituents on the adjacent carbon atom are in the R configuration; the prefix S represents that the substituents on the adjacent carbon atom are in the S configuration; R.sub.1 is hydrogen or hydroxy and R.sub.2 is hydroxy or .beta.-glucopyranosyloxy, and to the hydrates and salts thereof, especially pharmaceutically acceptable salts. The compounds of formula I are prepared by fermentation using the strain So ce 12 (NCIB 12134) of the species Sorangium celulosum and are effective antiobiotics.

Macrocyclic antibiotics

Growing community of inventors

Braunschweig, Germany

Rolf Jansen